Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating, Announces Target Price $100
Sector Update: Health Care Stocks Rise Pre-Bell Friday
Express News | Exact Sciences Shares up 1.2% Premarket After FDA Approves Co's Colorectal Cancer Screening Test
Express News | Exact Sciences Corp - Cologuard Plus Test Expected to Launch With Medicare Coverage in 2025
FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
Express News | FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
Exact Sciences Corporation's (NASDAQ:EXAS) Path To Profitability
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $80
Leerink Partners Maintains Exact Sciences(EXAS.US) With Buy Rating
Buy Rating for Exact Sciences as Cologuard Plus Poised for Growth and Upside Pricing Potential
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on These Healthcare Stocks: Exact Sciences (EXAS), AdaptHealth (AHCO)
Exact Sciences, Quanterix Extend Slide After Medicare Rates
Wolfe Research Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $75
Optimistic Outlook on Exact Sciences's Stock Despite CLFS Rate Stasis
Raymond James Reiterates Market Perform on Exact Sciences
Exact Sciences Analyst Ratings
Hyper Personalized Medicine Research Report 2024: A $5.5 Trillion Market in 2023 - Global Forecast to 2030 Featuring QIAGEN, Danaher, Illumina, GE, Exagen, Abbott, Exact Sciences, Dako, Decode
BTIG Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $82